| Methods |
4‐ to 5‐week placebo run‐in; inclusion criteria= mean sitting DBP 95‐110 mm Hg on days 22 and 29 (± 3 days) and, if necessary, day 36 (± 3 days) of run‐in; the two measurements could not differ by > 8 mm Hg; 8‐week double‐blind treatment |
| Participants |
All patients: n=319(220 males,99 females); mean age=52.8(10.2) years; baseline sitting SBP=149.8(13.6) mm Hg, DBP=100.7(4.2) mm Hg |
| Interventions |
Irbesartan 100 mg once daily;
Irbesartan 200 mg once daily;
Irbesartan 300 mg once daily;
Placebo;
taken in the morning |
| Outcomes |
Mean change from baseline in trough sitting SBP/DBP using mercury sphygmomanometer;
Mean change from baseline in peak sitting SBP/DBP using mercury sphygmomanometer;
WDAE |
| Notes |
BP change and SE of change reported, endpoint BP and SD not reported, baseline SD reported; calculated SD from N and SE; BP data from Table 2, p. 465; Jadad score=4; funding source= Bristol‐Myers Squibb |
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
